Recent Updates
Recently added Catalysts
WGS Positive Sentiment

GeneDx to Report Third Quarter 2026 Financial Results on Monday, November 9, 2026

Friday, October 23, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: GeneDx announced it will release its third quarter 2026 financial results on November 9, 2026. The company will hold a conference call at 4:30 p.m. Eastern Time to discuss these results. This announcement highlights GeneDx's ongoing commitment to transparency with investors.

Market Sentiment Analysis

POSITIVE FACTORS

  • GeneDx is a leader in rare disease diagnosis.
  • The company is focused on improving health through genomic data.
  • The upcoming financial results may provide insights into company performance.

Full Press Release Details

GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced it will release financial results for the third quarter of 2026 after the market closes on Monday, November 9, 2026. Management will host a conference call that day to discuss third quarter 2026 financial and operating results at 4:30 p.m. Eastern Time. Conference Call Details Investors interested in listening to the conference ca

Frequently Asked Questions

When will GeneDx report its Q3 2026 results?

GeneDx will report its Q3 2026 results on November 9, 2026.

What time is the conference call for Q3 2026 results?

The conference call is scheduled for 4:30 p.m. Eastern Time.

What is GeneDx known for?

GeneDx is a leader in rare disease diagnosis and genomic data.

How can investors listen to the conference call?

Investors can listen to the conference call by joining on the specified date.

ShareAdd on Google
Tags: WGS GeneDx financial results genomic data rare disease diagnosis
Last updated: Oct 23, 2026

Biotech snapshot

Cash runway
$133M liquidity · $10M/mo burn
~11 mo
Medium dilution risk